Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Radiology
Volume 2015, Article ID 731361, 4 pages
http://dx.doi.org/10.1155/2015/731361
Case Report

Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma

1Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, M-391, San Francisco, CA 94143-0628, USA
2Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, Room 779 M, San Francisco, CA 94143-0112, USA
3Department of Radiation Oncology, UCSF Long Hospital, 505 Parnassus Avenue, San Francisco, CA 94143-0226, USA

Received 22 December 2014; Revised 19 January 2015; Accepted 2 February 2015

Academic Editor: Marco Leonardi

Copyright © 2015 Ramon F. Barajas Jr. et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. W. Dewhirst, Y. Cao, and B. Moeller, “Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response,” Nature Reviews Cancer, vol. 8, no. 6, pp. 425–437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. Spence, M. Muzi, K. R. Swanson et al., “Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival,” Clinical Cancer Research, vol. 14, no. 9, pp. 2623–2630, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Bruehlmeier, U. Roelcke, P. A. Schubiger, and S. M. Ametamey, “Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O–H2O,” Journal of Nuclear Medicine, vol. 45, no. 11, pp. 1851–1859, 2004. View at Google Scholar · View at Scopus
  5. H. J. Tochon-Danguy, J. I. Sachinidis, F. Chan et al., “Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO),” Nuclear Medicine and Biology, vol. 29, no. 2, pp. 191–197, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. P. E. Valk, C. A. Mathis, M. D. Prados, J. C. Gilbert, and T. F. Budinger, “Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole,” Journal of Nuclear Medicine, vol. 33, no. 12, pp. 2133–2137, 1992. View at Google Scholar · View at Scopus
  7. M. Zimny, B. Gagel, E. DiMartino et al., “FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 12, pp. 1426–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. L. M. Cher, C. Murone, N. Lawrentschuk et al., “Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies,” Journal of Nuclear Medicine, vol. 47, no. 3, pp. 410–418, 2006. View at Google Scholar · View at Scopus
  9. J. Rieger, O. Bähr, K. Müller, K. Franz, J. Steinbach, and E. Hattingen, “Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients,” Journal of Neuro-Oncology, vol. 99, no. 1, pp. 49–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. R. Gerstner, M. P. Frosch, and T. T. Batchelor, “Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab,” Journal of Clinical Oncology, vol. 28, no. 6, pp. e91–e93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. E. R. Gerstner, M. P. Frosch, and T. T. Batchelor, “Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab,” Journal of Clinical Oncology, vol. 28, no. 6, pp. e91–e93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. F. Barajas Jr., J. L. Rubenstein, J. S. Chang, J. Hwang, and S. Cha, “Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma,” American Journal of Neuroradiology, vol. 31, no. 1, pp. 60–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Sugahara, Y. Korogi, M. Kochi et al., “Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas,” Journal of Magnetic Resonance Imaging, vol. 9, no. 1, pp. 53–60, 1999. View at Google Scholar
  14. S. Mong, B. M. Ellingson, P. L. Nghiemphu et al., “Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls,” The American Journal of Neuroradiology, vol. 33, no. 9, pp. 1763–1770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. R. K. Jain, “Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function,” Journal of Controlled Release, vol. 74, no. 1–3, pp. 7–25, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Y. Wen, D. R. Macdonald, D. A. Reardon et al., “Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1963–1972, 2010. View at Publisher · View at Google Scholar · View at Scopus